{"id":"dimenoxadol","rwe":[{"pmid":"6139983","year":"1983","title":"GABA-opiates interactions in the activity of analgesics.","finding":"","journal":"Archives internationales de pharmacodynamie et de therapie","studyType":"Clinical Study"}],"tags":[{"label":"dimenoxadol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"estocin","offLabel":[],"synonyms":["dimenoxadol","dimenoxadole","dimenoxadol hydrochloride","estocin","dimenoxadol HCl"],"timeline":[],"approvals":[],"brandName":"Estocin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"dimenoxadol","explanation":"Think of neurotransmitters like messengers that help different parts of the brain talk to each other. Estocin helps regulate the way these messengers work, which can affect how we feel pain and other sensations. By fine-tuning this process, Estocin may help reduce pain and discomfort.","oneSentence":"Estocin works by modulating the activity of certain neurotransmitters in the brain.","technicalDetail":"Estocin is a mu-opioid receptor agonist and NMDA receptor antagonist, which suggests that it may work by activating certain opioid receptors while blocking the activity of NMDA receptors in the brain."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3149","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIMENOXADOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:43:37.137432","biosimilars":[],"competitors":[],"genericName":"dimenoxadol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"4D65PBX0VK","CHEBI":"CHEBI:135396","INN_ID":"710","UMLSCUI":"C0058194","ChEMBL_ID":"CHEMBL2104309","DRUGBANK_ID":"DB01461","PUBCHEM_CID":"17036","MESH_SUPPLEMENTAL_RECORD_UI":"C005016"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"1983 Sep","pmid":"6139983","title":"GABA-opiates interactions in the activity of analgesics.","journal":"Archives internationales de pharmacodynamie et de therapie"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Estocin, also known as Dimenoxadol, is a small molecule drug in the dimenoxadol class. Its exact target is unknown, but it is believed to work by modulating the activity of certain neurotransmitters in the brain. Estocin is not FDA-approved for any indications, and its commercial status is unclear. As a result, there is limited information available on its safety profile and potential side effects. Further research is needed to fully understand the properties and potential uses of Estocin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}